Experimental cancer drug combo trial halted early
NCT ID NCT03426371
First seen May 13, 2026 · Last updated Jun 19, 2026 · Updated 4 times
Summary
This phase 3 trial tested a drug called A140 (similar to cetuximab) combined with chemotherapy (mFOLFOX6) as a first treatment for people with a specific type of advanced colorectal cancer (RAS wild-type). The study planned to enroll 570 people in China but was terminated early with only 52 participants. The goal was to see if the combination slowed cancer growth and improved survival. Because the trial stopped early, the results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
307 Hospital of PLA
Beijing, Beijing Municipality, 100071, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
A140 (a biosimilar to cetuximab) plus chemotherapy (mFOLFOX6)
What this could lead to
If successful, this could provide a new treatment option for people with a specific type of advanced colorectal cancer.
What could go wrong
The trial was terminated early with only 52 participants instead of the planned 570, so results are very limited and may not be reliable. It is unclear if A140 works better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.